19 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
29 May 24
Current report (foreign)
6:24am
who are involved in R&D, manufacturing and quality. ✓ The Company conducts various risk assessments and assurance activities in relation to data … privacy and Artificial Intelligence (AI) risks. ✓ The Company conducted the following actions for cybersecurity: ◆ Since the Company recognized
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
30 May 23
Current report (foreign)
6:19am
to manage our exposure to digital threats and strengthen adherence to compliance and data privacy standards across our online channels. Our significant
6-K
EX-99.1
dajify
29 Jun 21
Current report (foreign)
7:38am
6-K
EX-99.1
esoe9h
17 Dec 20
Current report (foreign)
6:01am
6-K
d5lgwf
29 May 20
Current report (foreign)
6:20am
6-K
EX-99.1
kfxg4a5pwoq3u9baiimh
10 Jan 20
Better Health, Brighter Future 2019 SUSTAINABLE VALUE REPORT Takeda Pharmaceutical Company Limited
6:36am
424B3
v4rn75nr311x0 ts
14 Nov 19
Prospectus supplement
6:10am
F-4/A
so7s4vhbtlban3 net7
12 Nov 19
Registration of securities (foreign) (amended)
9:50am
F-4
kum tlwjh1dm
9 Aug 19
Registration of securities (foreign)
6:27am
20-F
1lfvdvq8k7 8b3do
27 Jun 19
Annual report (foreign)
6:41am
20FR12B/A
uaaxtss
17 Dec 18
Initial registration of securities (foreign private issuers) (amended)
6:14am
20FR12B
vpwg 07krhqui5
6 Dec 18
Initial registration of securities (foreign private issuers)
10:39am
DRS/A
wpqonspesii5atdr
16 Nov 18
Draft registration statement (amended)
12:00am
SC TO-T
EX-99
878ib2z
30 Apr 18
Third party tender offer statement
6:13am
- Prev
- 1
- Next